exactly, if share price is not in the range of $30 ~ $80, just on par with our peers, it will be a shame!
Go check Bloomberg Business report entitled "
short-Selling Herds Finding April Is the Cruelest Month Since 2009"
See how shorts have sucked big times including NWBO shorts as the one of 17 most sucking shorts ever in April, a usual profiting month for shorts!
I 100% agree with your stance, and I have never sold a single share since German HE news came out last year. Good luck to you and all who dare (will) hold their shares until our share price is at least on par with its peers'!
The trend upward will continue since there is no sale pressure and since any shares sold seem to be picked up by someone hungered for more!
This should give you a comfort to hold this stop until at least $40 is reached just on par of the lowest stock price of our peers!
Reasonable range should be from a couple of months (first interim results and recommendation) to less than one year for final results of the trial if it is not stopped in both 1st and 2nd interims.
Just repeat of these results from P3 trial, stock price goes instantly into the range of $60 ~ $100!
Before any mention of nwbo preceded with the word of controversial, since last a couple weeks ago, it has abandoned that word. Today's article is yet another prove:
" Novartis' 'megablockbuster' heart drug LCZ696 wins another rave preview
April 23, 2015 By John Carroll
Readying itself for what looks like a blockbuster victory lap in the cardiovascular field, Novartis ($NVS) has notched boasting rights for its heart drug LCZ696, gaining recognition in the U.K. as a "promising innovative medicine" that could be made available to patients ahead of formal marketing approval.
Novartis Pharma Chief David Epstein
The Medicines and Healthcare products Regulatory Agency, or MHRA, granted the designation earlier today as an opening move toward early access. And they were moved by the PARADIGM-HF Phase III study, which demonstrated some clear benefits in reducing cardio deaths.
The MHRA isn't going to get any kickback from Novartis. Novartis pharma chief David Epstein has already dubbed this drug a "megablockbuster" in the making. And Thomson Reuters just days ago estimated 2019 sales for this drug at $3.73 billion.
The stellar data and a breakthrough reputation on both sides of the Atlantic helped chill expectations for Amgen's ($AMGN) newly approved heart treatment Corlanor (ivabradine). Even some concerns about a potential link to Alzheimer's--recently outlined by French researchers--has barely shaken the faith for LCZ696.
Last month the MHRA selected Merck's Keytruda, the closely-watched PD-1 checkpoint inhibitor, as the pioneer therapy to win early market access in the U.K. Northwest Biotherapeutics ($NWBO), meanwhile, won the first PIM last fall for its cancer vaccine DCVax.
"Despite widespread use of available treatments and implementation of NICE heart failure guidelines, outcomes remain poor for those diagnosed, with around 60% dying from heart failure within five years," says Hugh O'Dowd, the general manager at Novartis UK & Ireland. "" ...
I may be wrong on her true position, so my apology to her, and I would like to sincerely invite her to YMB as she seemed to quit posting in Ihub.
She is thought to be part of FUD team spearheaded by Pyrr, supported by koman, Iclight, Austine, etc., including her as one of the conversation "couple" (the other one is Pyrr).
All just speculation as I speculate the price should be and must be in the range of $30 ~ $80 before the final results of either L and D are known just on par with our peers of juno, kite, blue and cldx.
Otherwise we as investors and the management collectively just have not done our jobs satisfactorily or to the standard!
This is indeed the essence. If you have done your DD, a cashmere sweater may just be an insult!
I agree. One of those days we wake up with middle double digit stock price with no wondering but just smile!
No data from any other companies are better than or even close to these data achieved by NWBO!